Inactive Instrument

Polydex Pharmaceuticals Limited Stock price

Equities

POLXF

BS7317282002

Pharmaceuticals

Dynamic Chart
Biospectra, Inc. and BioSpectra Canada, Ltd completed the acquisition of Polydex Pharmaceuticals Limited (OTCPK:POLX.F). CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2023 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2023 CI
Biospectra, Inc. and BioSpectra Canada, Ltd entered into an agreement to acquire Polydex Pharmaceuticals Limited (OTCPK:POLX.F) for $6.9 million. CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022 CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Revenue $858,089 MT
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Loss $-0.11 MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended July 31, 2022 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2022 CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Posts Q1 Revenue $1.2M MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
Polydex Pharmaceuticals Limited Enters into an Agreement with Termanox Water Treatment Solutions for A Novel Use of Its Native Dextran Product CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021 CI
Polydex Pharmaceuticals : Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q2 Revenue $1.34M MT
More news
Managers TitleAgeSince
Chief Executive Officer 65 81-12-31
Director of Finance/CFO 58 18-10-31
Chief Operating Officer 71 83-12-31
Members of the board TitleAgeSince
Chief Executive Officer 65 81-12-31
Director/Board Member 84 82-12-31
Director/Board Member 81 97-12-31
More insiders
Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company's products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.
More about the company
  1. Stock
  2. Equities
  3. Stock Polydex Pharmaceuticals Limited - OTC Markets